Ascentage Pharma Group International
HKSE: 6855.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dajun Yang
- Employees
- 567
- Headquarters
- Suzhou, China
- IPO year
- 2019
- Market cap
- HK$15.9B
- Website
- https://www.ascentagepharma.com
Loading 6855…
Loading profile data…Frequently asked questions about 6855
What does Ascentage Pharma Group International (6855.HK) do?
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well...
Where does 6855.HK trade?
Ascentage Pharma Group International (6855.HK) trades on the Hong Kong Stock Exchange.
What sector is 6855.HK in?
Ascentage Pharma Group International (6855.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ascentage Pharma Group International?
Dajun Yang is the chief executive officer of Ascentage Pharma Group International (6855.HK).
Where is Ascentage Pharma Group International headquartered?
Ascentage Pharma Group International is headquartered in China.
Does 6855.HK pay a dividend?
Ascentage Pharma Group International (6855.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6855.HK go public?
Ascentage Pharma Group International (6855.HK) completed its initial public offering in 2019.